VidPrevtyn Beta, from Sanofi and GSK, has become the first COVID-19 vaccine to win EU marketing approval based on immunobridging trials.
Well-justified and appropriately designed immunobridging studies that compare an investigational vaccine with an approved one “are adequate for authorizing future COVID-19 vaccines at this point in the pandemic,” said the European Medicines Agency, whose recommendation